imaGenes GmbH Adds Third Roche NimbleGen Certification to Service Portfolio for Comparative Genomic Hybridization

MADISON, Wis.--(BUSINESS WIRE)-- Roche NimbleGen (SIX:RO)(SIX:ROG)(OTCQX:RHHBY) is pleased to announce that imaGenes GmbH, located in Berlin, Germany, has passed the certification process to qualify as a Roche NimbleGen Certified Service Provider (CSP) for Comparative Genomic Hybridization (CGH). imaGenes is a solution provider for functional genomics and proteomics with a comprehensive portfolio of high-quality services for molecular life sciences. This is the third Roche NimbleGen certification for imaGenes to provide service for NimbleGen arrays. This follows the successful certification for ChIP-chip in December 2009 and DNA methylation analysis in February 2010, and makes imaGenes the first service provider in Europe with the CGH certification.

With this announcement, imaGenes now offers CGH using the comprehensive array workflow from Roche NimbleGen, which includes the NimbleGen MS 200 Microarray Scanner, arrays, reagents and software. CGH is an important array-based tool that allows for the detection of chromosomal abnormalities, copy number variations, and specific break-points at much higher resolution over conventional methods. The genome-wide and disease associated region focused analysis on these types of chromosomal changes allows for a clearer understanding of the genome and how these changes can impact disease. This in-depth information will help researchers to develop future methods and tools to better diagnose and treat these diseases.

“The comprehensive portfolio of Roche NimbleGen certified services enables imaGenes to offer any functional DNA analysis to its customers in consistent high quality. Roche NimbleGen is our reliable partner en route to become the premier service provider for both biomarker development and clinical research applications,” says Dr. Johannes Maurer, Director Genomic Products & Marketing at imaGenes.

“Roche NimbleGen is extremely pleased to partner with a company that has such a strong commitment to building up their service business and expanding the solutions they offer to the genomics market. We are excited about the addition to their service portfolio of our cutting-edge NimbleGen CGH arrays and the establishment of our first CGH CSP in Europe. imaGenes has once again demonstrated their technical expertise and business acumen, this time in an area as dynamic and fast growing as the array based copy number detection market,” adds Dr. Frank Pitzer, CEO for Roche NimbleGen, Inc.

For more information about Roche NimbleGen, please visit www.nimblegen.com

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

For life science research only. Not for use in diagnostic procedures.

NIMBLEGEN is a trademark of Roche.

Other brands or product names are trademarks of their respective holders.



CONTACT:

Roche Diagnostics
Dr. Burkhard Ziebolz
Phone: +49 8856 604830
Email: [email protected]
or
Roche NimbleGen
Kary Staples
Phone: +1 608 218 7623
Email: [email protected]

KEYWORDS:   United States  Europe  Asia Pacific  North America  Switzerland  Japan

INDUSTRY KEYWORDS:   Stem Cells  Health  Biotechnology  Clinical Trials  Medical Devices  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.